RE:Leading Analyst, According to Mr.Hulot: JerkOffAdvocate. Here was RBC’ Equity Research on November 13, 2015. They were wrong then and they are wrong now. The Truth is somewhere in between but MUCH higher than now. We’ll see
Concordia Healthcare Corp.
Strong Q3 -Looking Forward to the AMCo
Contribution
Our view: The Q3 results, which were the first quarter to see a full quarter
of Covis revenues, exceeded our expectations and beat consensus. Legacy
revenues of $90.6MM came in above our anticipated $85.0MM. Our
outlook remains unchanged and we remain buyers of CXRX given the recent share price weakness.
Outperform
NASDAQ: CXRX; USD 28.54; TSX: CXR
Price Target USD 77.00